Specialist info: Breast cancer
Explore our latest news, features and educational resources in this specialist area.
Regulatory Alerts, GP info: Cancer, Specialist info: Oncology, Specialist info: Breast cancer, Oncology Room
New triple negative advanced breast cancer drug too expensive for NHS use, says NICE
NICE has issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
Regulatory Alerts, GP info: Cancer, Specialist info: Oncology, Specialist info: Breast cancer, Oncology Room
Alpelisib with fulvestrant not recommended for advanced breast cancer
NICE has issued draft guidance which does not recommend the treatment based on limitations in the clinical evidence and cost-effectiveness uncertainties.
Regulatory Alerts, GP info: Cancer, Specialist info: Oncology, Specialist info: Breast cancer, Oncology Room
Tucatinib now recommended for advanced breast cancer in NICE final draft guidance
The new recommendation comes after the company provided further analyses to demonstrate its the treatment’s benefit, especially for people with brain metastases.
Regulatory Alerts, GP info: Cancer, Specialist info: Oncology, Specialist info: Breast cancer, Oncology Room
SMC accepts treatment for breast cancer
Pertuzumab/trastuzumab is accepted for restricted use within NHS Scotland in line with previous SMC advice for pertuzumab and trastuzumab.
Regulatory Alerts, GP info: Cancer, Specialist info: Oncology, Specialist info: Breast cancer, Oncology Room
Drug Safety Update: CDK4/6 inhibitors
The MHRA has warned of reports of interstitial lung disease and pneumonitis, including severe cases, with CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼)
